Replies to post #197746 on Biotech Values

[Bickema]

December will be exciting. Hard to imagine where the SP could be if EGRX is able to go 3 for 3.

Do you have any opinion of Fibogen at current valuation?

I know Roxadustat is a few years out from Approval but could be a blockbuster. the company appears well funded.

[DewDiligence]

Bullish (but half-baked) EGRX write-up from TheStreet.com:

http://www.thestreet.com/story/13380098/2/eagle-a-bright-spot-in-pharma-landscape.html

The write-up doesn’t even mention EGRX’s programs for Docetaxel, Angiomax, and Alimta!